Literature DB >> 24837212

Shengxian decoction in chronic heart failure treatment and synergistic property of Platycodonis Radix: a metabolomic approach and its application.

Feng Zhang1, Qin Zhan, Xin Dong, Bo Jiang, Lianna Sun, Shouhong Gao, Zhiqing He, Xia Tao, WanSheng Chen.   

Abstract

Shengxian Decoction (SXT), a classic Traditional Chinese Medicine (TCM) prescription, consists of five TCMs: Astragali Radix, Anemarrhenae Rhizoma, Bupleuri Radix, Platycodonis Radix (PG), and Cimicifugae Rhizoma. SXT has been demonstrated to show good therapeutic effects on the cardiovascular system. A metabolomic approach was applied to study its therapeutic mechanisms and the synergistic properties of PG. UPLC-Q-TOF/MS based metabolomic profiling was adopted to assess the intervention effects of SXT, SXT-PG (SXT lacking PG) and PG, on chronic heart failure (CHF) rats. Betaloc was used as a positive control drug. A supervised discriminant technique (PLS-DA) was used to visualize the difference in global metabolic profiles within all experimental groups. Some significantly changed metabolites, such as carnitines, long-chain fatty acids and sphinganines, were identified, and the biochemical alterations of these were related to the disturbance in serum metabolic profiling of CHF rats. Furthermore, the metabolomics study demonstrated that the administration of SXT, but neither SXT-PG or PG alone, gave satisfactory curative effects on CHF through partially regulating the perturbed metabolic pathways. These observations were demonstrated by histopathological, electrocardiogram and serum enzymatic investigations. All these results supported the TCM theory that PG possesses synergistic properties which promote the synergized herbs in SXT in CHF rats. Overall, this paper demonstrates that metabolomics offers opportunities to understand the therapeutic mechanisms and synergistic properties of TCM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24837212     DOI: 10.1039/c4mb00055b

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  2 in total

1.  Shengxian decoction decreases doxorubicin‑induced cardiac apoptosis by regulating the TREM1/NF‑κB signaling pathway.

Authors:  Lei Yao; Mingtai Gui; Jianhua Li; Bo Lu; Jing Wang; Xunjie Zhou; Deyu Fu
Journal:  Mol Med Rep       Date:  2021-01-26       Impact factor: 2.952

2.  Integrated UPLC-Q/TOF-MS Technique and MALDI-MS to Study of the Efficacy of YiXinshu Capsules Against Heart Failure in a Rat Model.

Authors:  Jing Xu; Xianyu Li; Fangbo Zhang; Liying Tang; Junying Wei; Xiaoqing Lei; Huanhuan Wang; Yi Zhang; Defeng Li; Xuan Tang; Geng Li; Shihuan Tang; Hongwei Wu; Hongjun Yang
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.